Across TCGA pan-cancer cohorts, GPR25 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GPR25 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GPR25 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPR25 expression acts as an unfavorable survival marker.
HNSC are the cancer types where GPR25 Mutation most reproducibly stratifies survival.